PsyBio Therapeutics Inc.

TSX-V: PSYB

Company Logo

Company Overview

PsyBio Therapeutics is a biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health and other disorders.

The team has experience in drug discovery based on synthetic biology as well as clinical and regulatory experience moving drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof.

The company is also researching and developing new non-naturally occurring molecular structures which may have unique therapeutics properties.

Financial Highlights

$0

Revenue (ttm)

-$1,534,553

Gross Profit (ttm)

-$0.09

Diluted EPS (ttm)

Management Team

Mr. Evan M. Levine
Co-Founder, CEO & Chairman

Mr. Noah Isidore Davis
CFO, Sec. & Director

Mr. Ross Carmel
Chief Legal Officer & Director

Dr. Michael Spigarelli M.B.A., M.B.E., M.D., Ph.D.
Chief Medical Officer

Mr. Andrew Jones
Inventor & Chairman of Scientific Advisory Board

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
()

Insider Ownership
1%